Making A DifferenceBrazil: SC Authorises Probe To Investigate President Bolsonaro’s Response To Covaxin DealBY Associated Press
NationalPhase Three Clinical Trial Concludes 77.8 Per Cent Effectiveness Of CovaxinBY Outlook Web Desk
NationalPregnant Women Now Eligible For Covid Vaccine, Can Register On CoWin Or Walk-InBY Outlook Web Bureau
Making A DifferenceFollowed Standard Approach For Contracts, Regulatory Approvals In Brazil: Bharat BiotechBY Outlook Web Bureau
NationalIndia's Covaxin Effectively Neutralises Delta Variant, Says US National Institute Of HealthBY Outlook Web Desk
Making A DifferenceBrazil Temporarily Suspends Covaxin Contract, Bolsonaro Under Fire For 'Graft'BY Outlook Web Desk
NationalNo Evidence To Suggest Delta Plus Variant Impacts Vaccine Efficacy: Covid Task Force ChiefBY PTI
Making A DifferenceExplained: Why Is The Brazil Government Under The Scanner For Its Covaxin Contract?BY Outlook Web Bureau
NationalCovishield, Covaxin Effective Against Alpha, Beta, Gamma And Delta Covid Variants: CentreBY Outlook Web Bureau
NationalMost Vulnerable Should Get Vaccine Second Dose At Eight Weeks: Prof Srinath ReddyBY Preetha Nair
NationalFact Check: Does Covaxin Final Product Have Newborn Calf Serum? Here’s The TruthBY Outlook Web Bureau
NationalRisk Of Dying Post Vaccination Negligible Compared To Risk Of Death Due To Covid: GovtBY Outlook Web Bureau
NationalSupply Of Covaxin At Rs 150 Per Dose To Centre Not Sustainable In Long Run: Bharat BiotechBY Outlook Web Bureau
NationalSingle Dose Of Covid Vaccine Sufficient For Those Already Infected, Says StudyBY Outlook Web Bureau
Making A DifferenceFDA Has Rejected Covaxin’s Emergency Use In America; Here’s WhyBY Outlook Web Bureau
NationalCovaxin To Be Administered In National Capital Only As Second Dose: Delhi Govt To HCBY Outlook Web Bureau
NationalCovaxin Only For 18-44 Age Group Who Are Eligible For Second Dose: Delhi GovtBY Outlook Web Bureau
NationalAIIMS Delhi To Start Screening Children For Clinical Trials Of Covaxin From TodayBY Outlook Web Bureau